Clinical Trials Logo

Clinical Trial Summary

This study is asses the hematological changes in children with chronic kidney disease stage 3 to 5 including - Complete blood picture - Coagulation profile (PT, PC, PTT) - Iron study


Clinical Trial Description

Chronic kidney disease (CKD) is a major public health issue with an increasing incidence and prevalence worldwide. In CKD, hematological parameters are influenced, it is associated with high morbidity and mortality rates, but there have been very few studies on the hematological profile of children with chronic kidney disease, on follow-up in general, and particularly among chronic kidney disease patients(Melaku.,et al 2022). CKD is defined by the presence of kidney damage or an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2, it can last for 3 months or longer, regardless of the cause. Chronic kidney disease (CKD) is recognized as a major non-communicable disease in children. (Inker.,et al2014). CKD is classifies it into 6 categories based on glomerular filtration rate (G1 to G5 with G3 split into 3a and 3b). It also includes the staging based on three levels of albuminuria (A1, A2, and A3), with each stage of CKD being sub-categorized according to the urinary albumin-creatinine ratio in (mg/gm) or (mg/mmol) in an early morning "spot" urine sample.( Inker,.et al 2012) The 6 categories include: - G1: GFR 90 ml/min per 1.73 m2 and above - G2: GFR 60 to 89 ml/min per 1.73 m2 - G3a: GFR 45 to 59 ml/min per 1.73 m2 - G3b: GFR 30 to 44 ml/min per 1.73 m2 - G4: GFR 15 to 29 ml/min per 1.73 m2 - G5: GFR less than 15 ml/min per 1.73 m2 or treatment by dialysis The three levels of albuminuria include an albumin-creatinine ratio (ACR) - A1: ACR less than 30 mg/gm (less than 3.4 mg/mmol) - A2: ACR 30 to 299 mg/gm (3.4 to 34 mg/mmol) - A3: ACR greater than 300 mg/gm (greater than 34 mg/mmol). (Inker.,et al2014). hematological parameters such as white blood cell (WBC) include total leukocyte and differential counts, platelet (PLT), and red blood cell (RBC). Parameters, Kidney function ,electrolytes such as Na,k,ca and liver function bleeding time, and pro-thrombin time, are usually affected in CKD . These are common in CKD due to erythropoietin deciency and other factors such as increased hemolysis, suppression of bone marrow erythropoiesis, hematuria, and gastro intestinal blood loss. (George.,et al2015). All CKD patients, particularly those with an estimated GFR (eGFR) < 60 mL/min/1.73 m2, should be screened for anemia on initial evaluation for CKD. Anemia is defined as Hb < 13 g/dL in men and Hb < 12 g/dL in women, according to WHO criteria. (Hira Shaikh.,et al 2023). the primary cause of anemia in patients with CKD is insufficient production of erythropoietin by the diseased kidneys. Other factors include iron, folate & B12 deficiency due to nutritional insufficiency or increased blood loss (Hira Shaikh.,et al 2023). acute and chronic inflammation with impaired iron utilization, sever hyperparathyroidism with consequent bone marrow fibrosis and shortened red cell survival in the uremic environment, bleeding due to dysfunctional platelets, and rarely blood loss from hemodialysis(Hira Shaikh.,et al 2023). Criteria used to define iron deficiency are different among CKD compared to normal renal function. Among CKD patients, absolut iron deficiency is defined when the transferrin saturation (TSAT) is ≤20% and the serum ferritin concentration is ≤100 ng/mL among predialysis and peritoneal dialysis patients or ≤200 ng/mL among hemodialysis patients. Functional iron deficiency, also known as iron-restricted erythropoiesis, is characterized by TSAT ≤20% and elevated ferritin levels. (TSAT = plasma iron divided by the total iron-binding capacity × 100)( Cappellini .,et al 2017) . untreated prolonged anemia leads to a number of physiologic disorders, including: cardiovascular complications like decreased tissue oxygenation, increased cardiac output, ventricular dilatation and ventricular hypertrophy and increased mortality and morbidity.( Dwijen Das ., et al 2015). Iron supplementation is recommended for all CKD patients with anemia. There is general agreement according to guidelines that intravenous (i.v.) iron supplementation is the preferred method for CKD patients on dialysis (CKD stage 5D) and either i.v. or oral iron is recommended for patients with CKD(Tolkien.,et al 2015) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06143098
Study type Observational
Source Assiut University
Contact Zeinab Othman
Phone 01280234771
Email zeinabothman9090@gmail.com
Status Not yet recruiting
Phase
Start date March 1, 2024
Completion date January 31, 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03277911 - Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases N/A
Active, not recruiting NCT04008810 - Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
Completed NCT05144971 - StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
Active, not recruiting NCT05356325 - FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.
Not yet recruiting NCT04491669 - Screening of Gastrointestinal Tract Bleeding Causes Among Chronic Renal Failure Patients
Completed NCT04709120 - Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection
Terminated NCT03277183 - Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Phase 4
Enrolling by invitation NCT04491227 - Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
Recruiting NCT06279429 - Sucrosomial Iron on Insomnia in Non-dialysis Chronic Kidney Disease Patients With Iron Deficiency Anemia N/A
Recruiting NCT03501745 - Smart-CKD/BP Study N/A
Recruiting NCT04708743 - The Tongue Features Associated With Chronic Kidney Disease
Completed NCT04119570 - CKD Report Card Pilot Trial N/A
Completed NCT06374043 - Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. Phase 4
Not yet recruiting NCT06094920 - Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Phase 4
Recruiting NCT04819217 - Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease N/A
Completed NCT05970094 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Withdrawn NCT04782297 - Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)
Recruiting NCT05784389 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Recruiting NCT04630132 - Renal Ageing-sarcopenia Network
Not yet recruiting NCT05243979 - The Relation Between Thyroid , Parathyroid Hormones and eGFR in CKD Patients in Assiut